Nonetheless, our evidence that levetiracetam does not restrain, both in vitro and in vivo, the growth of SV2A-negative T23 tumor cells, likely excludes the relevance of HDAC- inhibition properties of this drug in our setting. This evidence concerns the gene HDAC9 and neoplasm.